Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Acquires CLC Bio

Premium

Qiagen has acquired CLC Bio, a privately held bioinformatics software company headquartered in Aarhus, Denmark.

The news was first reported on AllSeq's blog. GenomeWeb independently confirmed the information with a source familiar with the deal. A CLC Bio official declined to comment. Qiagen did not respond to requests for comment as of press time.

CLC Bio develops and markets software for analyzing genomic data from next generation sequencing platforms and traditional Sanger sequencing instruments. Its product portfolio includes tools such as the CLC Genomics Workbench, the CLC Main Workbench, and the CLC Genomics Server.

This is the second bioinformatics company that Qiagen has purchased this year. In May, it bought Ingenuity Systems for $105 million in cash to offer its life science and clinical customers a complete and integrated workflow for its PCR- and next-generation sequencing-based molecular testing solutions (BI 5/3/2013).

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.